Blog
RSS FeedPosted by Michael Wonder on 14 Mar 2024
ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 01 Feb 2024
ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...
Posted by Michael Wonder on 27 Jan 2024
ICER publishes evidence report on treatment for schizophrenia
25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...
Posted by Michael Wonder on 08 Jan 2024
ICER publishes final evidence report on treatment for pulmonary arterial hypertension
8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; ...
Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 25 May 2023
ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
Posted by Michael Wonder on 20 Oct 2022
ICER publishes final evidence report and policy recommendations on treatments for obesity management
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
Posted by Michael Wonder on 13 Sep 2022
ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 15 Feb 2022
ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
Posted by Michael Wonder on 03 Feb 2022
ICER releases draft evidence report on treatments for COVID-19
3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public ...